Company Overview
Snapshot
Founded in September 2008 by Eliahu Kaplan, M.D., Novaremed operates with 1–10 employees. The company has raised over $67.16 million across 6 funding rounds and has secured funding from 3 investors. In September 2021, Novaremed expanded its pipeline through the acquisition of Metys Pharmaceuticals.
Business overview
Novaremed is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for chronic pain. Its core product, NRD.E1, is an orally active small molecule with a novel mechanism of action, holding FDA Fast Track Designation and IND-approval for a Phase 2b clinical trial targeting painful diabetic peripheral neuropathy. The company's pipeline also includes MP-101 for chemotherapy-induced peripheral neuropathy and MP-103 in preclinical stages. Novaremed operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceutical market.
Strategic signal
In July 2022, Novaremed entered into an exclusive option and license agreement with NeuroFront for its non-opioid neuropathic pain treatment, NRD.E1, covering Greater China and Singapore. This agreement signals a strategic move towards international market expansion and validates the therapeutic potential of NRD.E1, indicating growing confidence in its commercial viability and its role in addressing the global demand for non-addictive pain management solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is Novaremed's lead product?
- Novaremed's lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action. It has received FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy.
- When did Novaremed acquire Metys Pharmaceuticals?
- In September 2021, Novaremed acquired Metys Pharmaceuticals, expanding its pipeline of non-opioid treatment candidates for chronic pain indications.
- Has Novaremed received any FDA designations for its products?
- Yes, in December 2020, Novaremed received Fast Track Designation from the FDA for NRD.E1 for the treatment of painful diabetic peripheral neuropathy.
- What was a key strategic partnership for Novaremed in 2022?
- In July 2022, Novaremed entered into an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore.
- When did Novaremed announce the publication of Phase 1 and Phase 2a study data for NRD.E1?
- In June 2022, Novaremed announced the publication of Phase 1 and Phase 2a study data for NRD.E1, demonstrating the potential of this investigational non-opioid pain treatment.